#SFHS2608106ADecree of 30 March 2026 on the delisting of pharmaceutical specialties from the list referred to in the first paragraph of Article L. 162-17 of the Social Security Code
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French decree removes two long-acting injectable risperidone products (OKEDI 100 mg and OKEDI 75 mg) manufactured by Laboratoires ROVI from the list of medicines reimbursable by French social security. The delisting takes effect four days after the decree is published in the Journal Officiel. Both presentations consist of pre-filled syringes of powder and solvent plus two needles. After the effective date, these specific formulations will no longer be reimbursed to insured persons under the French healthcare system.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Two OKEDI risperidone formulations (100 mg and 75 mg) are removed from the reimbursable medicines list
- Delisting takes effect on the 4th day following publication in the Journal officiel
- Both products are powder and solvent for prolonged-release injectable suspension in pre-filled syringes + 2 needles
+ 3 more changes with Pro
Obligations
What this law requires
Remove OKEDI 100 mg (risperidone) pre-filled syringes (CIP code 34009 302 487 5 1) from the list of reimbursable medicines effective 4 days after publication in the Journal Officiel
Remove OKEDI 75 mg (risperidone) pre-filled syringes (CIP code 34009 302 487 4 4) from the list of reimbursable medicines effective 4 days after publication in the Journal Officiel
Cease reimbursement to insured persons for OKEDI 100 mg and OKEDI 75 mg formulations manufactured by Laboratoires ROVI as of the effective date
Publish this decree in the Journal Officiel de la République française